EcoDrugPlus

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSFOG00015010069
Gene Symbol: ADAM17
3 Cross references
208 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSSFOG00015031640
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSSFOG00015020514
Gene Symbol: ADRM1
3 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSSFOG00015016396
Gene Symbol: AKT1
3 Cross references
197 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSSFOG00015027437
Gene Symbol: AKT2
3 Cross references
163 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSSFOG00015030606
Gene Symbol: AKT2
1 Cross references
209 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSSFOG00015017191
Gene Symbol: AKT3
3 Cross references
203 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSSFOG00015005123
Gene Symbol: ALK
1 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSSFOG00015014989
Gene Symbol: ABCC1
3 Cross references
201 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSSFOG00015001504
Gene Symbol: ABCC8
3 Cross references
229 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSSFOG00015006097
Gene Symbol: ABCC9
3 Cross references
235 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSSFOG00015018867
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).